ADDED
As a result of this segment realignment, the Company allocated goodwill to the reporting units existing under the new organizational structure on a relative fair value basis as of October 1, 2023.
Transformation costs represent non-recurring expenses for strategic projects with anticipated long-term benefits to the Company focused on cost reduction and productivity improvement that do not meet the definition of restructuring charges.
These costs are directed at simplifying, standardizing, streamlining, and optimizing the Company s operations, processes and systems to permanently alter the Company s operations for the long term.
For a project to be considered transformational, successful completion of the project must be expected to bring long-term material benefits to the organization and involve significant changes to process and/or underlying technology.
Transformation costs in the period result from actions taken as part of the Company s 2024 transformation plan and primarily relate to one time asset write downs associated with changes in technology, one time inventory write downs relating to restructuring actions taken in the period, and third-party consulting costs associated with process and systems re-design.
Core Products are Automated Stores, Cryogenic Systems, Automated Sample Tube, and Consumables and Instruments.
Revised amounts disclosed in the Company's Annual Report on Form 10-K for the year ended September 30, 2024.
As of March 31, 2025, 45,776,018 shares of the registrant s Common Stock, $0.01 par value, were outstanding.
As of December 1, 2025, 45,989,285 shares of the registrant s Common Stock, $0.01, par value, were outstanding.
Forward-looking statements may be identified by words such as expect, estimate, intend, believe, anticipate, may, will, should, could, continue, likely, or similar terms or variations.
REMOVED
Joseph Senior Vice President, General Counsel and Secretary true 21,000 Core Products are Automated Stores, Cryogenic Systems, Automated Sample Tube, and Consumables and Instruments.
As of March 28, 2024, 55,003,056 shares of the registrant s Common Stock, $0.01 par value, were outstanding.
As of November 19, 2024, 45,583,205 shares of the registrant s Common Stock, $0.01, par value, were outstanding.
All statements that are not historical facts, including statements about our beliefs or expectations, are forward-looking statements.
These statements may be identified by such forward-looking, terminology as expect, estimate, intend, believe, anticipate, may, will, should, could, continue, likely or similar statements or variations of such terms.
Such statements are based on current expectations and involve risks, uncertainties, and other factors which may cause the actual results, our performance or our achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
Such factors include those which are set forth in Part I, Item 1A Risk Factors in this Annual Report on Form 10-K and other documents we file from time to time with the Securities and Exchange Commission, or the SEC, such as our quarterly reports on Form 10 Q and our current reports on Form 8 K.
Unless the context indicates otherwise, references in this Annual Report on Form 10-K to we , us , our , the Company and other similar references refer to Azenta, Inc.
We now support our customers from research and clinical development to commercialization with our sample management, automated storage, vaccine cold storage and transport, as well as genomic services expertise to help our customers bring impactful and breakthrough therapies to market faster.
In total, we employ approximately 3,300 full-time employees, part-time employees and contingent workers worldwide as of September 30, 2024 and have sales in approximately 125 countries.